Carbamoylcholine, also known as carbachol, is a muscarinic agonist discovered in 1932. Carbamoylcholine was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects.
Carbamoylcholine was granted FDA approval on 28 September 1972.
Carbamoylcholine is indicated to induce miosis for surgery and to reduce intraocular pressure elevations in the first 24 hours after cataract surgery.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.